Biogen Inc Financials
Biogen Inc (BIIB) reported $9.9B in revenue for fiscal year 2025, up 2.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Biogen’s engine is a high-margin, low-capex model that keeps producing cash even as earnings wobble.
From FY2024 to FY2025, net margin fell from16.9% to13.1% . Even so, free cash flow margin remained20.7% because capital spending was only$154M , showing that this business converts earnings into cash mainly through low reinvestment needs rather than through expanding sales.
Gross margin moved from
Share buybacks dropped from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Biogen Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Biogen Inc, and counted as zero in the overall score.
Biogen Inc's revenue grew a modest 2.2% year-over-year to $9.9B. This slow but positive growth earns a score of 33/100.
Biogen Inc carries a low D/E ratio of 0.34, meaning only $0.34 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 66/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.68, Biogen Inc holds $2.68 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 72/100.
Biogen Inc converts 20.7% of revenue into free cash flow ($2.1B). This strong cash generation earns a score of 88/100.
Not available for Biogen Inc, and counted as zero in the overall score.
Biogen Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Biogen Inc generates $1.71 in operating cash flow ($2.2B OCF vs $1.3B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Biogen Inc generated $9.9B in revenue in fiscal year 2025. This represents an increase of 2.2% from the prior year.
Biogen Inc reported $1.3B in net income in fiscal year 2025. This represents a decrease of 20.8% from the prior year.
Biogen Inc earned $8.79 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 21.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Biogen Inc generated $2.1B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 24.7% from the prior year.
Biogen Inc held $3.0B in cash against $6.3B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Biogen Inc's gross margin was 75.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.4 percentage points from the prior year.
Biogen Inc's net profit margin was 13.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3.8 percentage points from the prior year.
Biogen Inc's ROE was 7.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 2.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Biogen Inc invested $1.8B in research and development in fiscal year 2025. This represents a decrease of 10.2% from the prior year.
Biogen Inc invested $153.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.1% from the prior year.
Not reported for fiscal year 2025.
BIIB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.9B | $9.9B+2.2% | $9.7B-1.6% | $9.8B-3.3% | $10.2B-7.4% | $11.0B-18.3% | $13.4B-6.5% | $14.4B+6.9% | $13.5B+9.6% | $12.3B+7.2% | $11.4B+6.4% | $10.8B+10.9% | $9.7B+40.0% | $6.9B+25.7% | $5.5B+9.3% | $5.0B |
| Cost of Revenue | $2.4B | $2.4B+4.1% | $2.3B-8.8% | $2.5B+11.2% | $2.3B+8.0% | $2.1B+16.9% | $1.8B-7.7% | $2.0B+7.7% | $1.8B+11.4% | $1.6B+10.2% | $1.5B+19.2% | $1.2B+5.9% | $1.2B+36.5% | $857.7M+57.2% | $545.5M+16.9% | $466.8M |
| Gross Profit | $7.5B | $7.5B+1.6% | $7.4B+0.9% | $7.3B-7.5% | $7.9B-11.0% | $8.9B-23.8% | $11.6B-6.3% | $12.4B+6.8% | $11.6B+9.3% | $10.6B+6.8% | $10.0B+4.7% | $9.5B+11.6% | $8.5B+40.5% | $6.1B+22.2% | $5.0B+8.5% | $4.6B |
| R&D Expenses | $1.9B | $1.8B-10.2% | $2.0B-19.0% | $2.4B+9.6% | $2.2B-10.8% | $2.5B-37.3% | $4.0B+75.0% | $2.3B-12.2% | $2.6B+15.2% | $2.3B+14.2% | $2.0B-2.0% | $2.0B+6.3% | $1.9B+31.1% | $1.4B+8.2% | $1.3B+9.5% | $1.2B |
| SG&A Expenses | $2.5B | $2.4B+1.2% | $2.4B-5.7% | $2.5B+6.1% | $2.4B-10.1% | $2.7B+6.8% | $2.5B+5.5% | $2.4B+12.7% | $2.1B+8.9% | $1.9B-0.7% | $1.9B-7.9% | $2.1B-5.3% | $2.2B+30.4% | $1.7B+34.0% | $1.3B+21.0% | $1.1B |
| Operating Income | N/A | N/A | N/A | N/A | N/A | $2.8B-37.6% | $4.6B-35.4% | $7.0B+19.6% | $5.9B+10.2% | $5.3B+3.8% | $5.2B+5.3% | $4.9B+23.1% | $4.0B+57.9% | $2.5B+35.5% | $1.9B+7.6% | $1.7B |
| Interest Expense | $275.1M | $267.5M+6.9% | $250.3M+1.4% | $246.9M+0.1% | $246.6M-2.8% | $253.6M+14.0% | $222.5M+18.7% | $187.4M-6.6% | $200.6M-20.0% | $250.8M-3.5% | $260.0M+172.3% | $95.5M+223.7% | $29.5M-7.5% | $31.9M-12.6% | $36.5M+10.6% | $33.0M |
| Income Tax | $251.1M | $263.6M-3.7% | $273.8M+102.4% | $135.3M-78.6% | $632.8M+1105.3% | $52.5M-94.7% | $992.3M-14.3% | $1.2B-18.8% | $1.4B-42.0% | $2.5B+98.7% | $1.2B+6.5% | $1.2B+17.3% | $989.9M+64.7% | $601.0M+27.7% | $470.6M+5.9% | $444.5M |
| Net Income | $1.4B | $1.3B-20.8% | $1.6B+40.6% | $1.2B-61.9% | $3.0B+95.8% | $1.6B-61.1% | $4.0B-32.1% | $5.9B+32.9% | $4.4B+74.5% | $2.5B-31.4% | $3.7B+4.4% | $3.5B+20.9% | $2.9B+57.6% | $1.9B+34.9% | $1.4B+11.8% | $1.2B |
| EPS (Diluted) | — | $8.79-21.4% | $11.18+40.3% | $7.97-61.8% | $20.87+100.7% | $10.40-58.1% | $24.80-21.1% | $31.42+45.6% | $21.58+81.0% | $11.92-29.6% | $16.93+10.4% | $15.34+24.0% | $12.37+58.4% | $7.81+35.6% | $5.76+14.3% | $5.04 |
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BIIB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $29.4B+5.0% | $28.0B+4.5% | $26.8B+9.3% | $24.6B+2.8% | $23.9B-3.0% | $24.6B-9.6% | $27.2B+7.7% | $25.3B+6.9% | $23.7B+3.4% | $22.9B+17.3% | $19.5B+36.3% | $14.3B+20.7% | $11.9B+17.1% | $10.1B+11.9% | $9.0B |
| Current Assets | $9.0B+20.3% | $7.5B+8.7% | $6.9B-29.9% | $9.8B+24.6% | $7.9B+14.1% | $6.9B-17.8% | $8.4B+9.7% | $7.6B-3.0% | $7.9B-9.8% | $8.7B+30.3% | $6.7B+47.7% | $4.5B+42.4% | $3.2B-1.8% | $3.2B+9.0% | $3.0B |
| Cash & Equivalents | $3.0B+26.7% | $2.4B+126.2% | $1.0B-69.3% | $3.4B+51.2% | $2.3B+69.9% | $1.3B-54.3% | $2.9B+137.9% | $1.2B-22.2% | $1.6B-32.4% | $2.3B+77.9% | $1.3B+8.6% | $1.2B+100.0% | $602.6M+5.6% | $570.7M+10.9% | $514.5M |
| Inventory | $2.2B-11.9% | $2.5B-2.6% | $2.5B+88.0% | $1.3B-0.5% | $1.4B+26.5% | $1.1B+32.9% | $804.2M-13.5% | $929.9M+3.0% | $902.7M-9.9% | $1.0B+12.1% | $893.4M+11.1% | $804.0M+22.0% | $659.0M+47.3% | $447.4M+36.9% | $326.8M |
| Accounts Receivable | $1.3B-4.4% | $1.4B-15.6% | $1.7B-2.4% | $1.7B+10.0% | $1.5B-19.0% | $1.9B+1.8% | $1.9B-4.0% | $2.0B+9.6% | $1.8B+24.0% | $1.4B+17.5% | $1.2B-5.1% | $1.3B+56.8% | $824.4M+20.0% | $686.8M+17.5% | $584.6M |
| Goodwill | $6.5B+0.2% | $6.5B+4.2% | $6.2B+8.2% | $5.7B-0.2% | $5.8B0.0% | $5.8B+0.1% | $5.8B+0.9% | $5.7B+23.2% | $4.6B+26.3% | $3.7B+37.7% | $2.7B+51.3% | $1.8B+42.8% | $1.2B+2.6% | $1.2B+4.8% | $1.1B |
| Total Liabilities | $11.2B-1.3% | $11.3B-5.9% | $12.0B+7.9% | $11.2B-13.6% | $12.9B-7.3% | $13.9B+0.3% | $13.9B+13.4% | $12.3B+10.9% | $11.1B+2.8% | $10.7B+6.1% | $10.1B+189.4% | $3.5B+8.0% | $3.2B+2.4% | $3.2B+20.7% | $2.6B |
| Current Liabilities | $3.3B-39.4% | $5.5B+61.0% | $3.4B+4.9% | $3.3B-23.9% | $4.3B+14.9% | $3.7B-23.1% | $4.9B+47.6% | $3.3B-2.2% | $3.4B-1.5% | $3.4B+32.7% | $2.6B+16.2% | $2.2B+26.2% | $1.8B+6.1% | $1.7B+81.6% | $912.9M |
| Long-Term Debt | $6.3B+38.3% | $4.5B-33.0% | $6.8B+8.1% | $6.3B+0.1% | $6.3B-15.5% | $7.4B+66.5% | $4.5B-24.9% | $5.9B | N/A | $16.4M-9.4% | $18.1M | N/A | $592.4M-13.8% | $687.4M-32.9% | $1.0B |
| Total Equity | $18.3B+9.2% | $16.7B+13.0% | $14.8B+10.5% | $13.4B+23.0% | $10.9B+1.8% | $10.7B-19.8% | $13.3B+2.3% | $13.0B+3.4% | $12.6B+3.9% | $12.1B+29.5% | $9.4B-13.3% | $10.8B+25.4% | $8.6B+23.8% | $7.0B+8.3% | $6.4B |
| Retained Earnings | $20.6B+6.7% | $19.3B+9.3% | $17.6B+7.1% | $16.5B+18.4% | $13.9B-0.5% | $14.0B-15.1% | $16.5B+1.2% | $16.3B+2.8% | $15.8B+4.9% | $15.1B+23.5% | $12.2B+31.5% | $9.3B+46.2% | $6.3B+41.5% | $4.5B+44.4% | $3.1B |
BIIB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.6B | $2.2B-23.3% | $2.9B+85.9% | $1.5B+11.8% | $1.4B-62.0% | $3.6B-13.9% | $4.2B-40.2% | $7.1B+14.4% | $6.2B+36.0% | $4.6B-0.8% | $4.6B+17.0% | $3.9B+33.2% | $2.9B+25.5% | $2.3B+24.7% | $1.9B+8.8% | $1.7B |
| Capital Expenditures | $167.9M | $153.8M+0.1% | $153.7M-44.5% | $277.0M+15.3% | $240.3M-6.9% | $258.1M-39.2% | $424.8M-17.4% | $514.5M-33.2% | $770.6M-11.2% | $867.4M+40.8% | $616.1M-4.2% | $643.0M+123.4% | $287.8M+16.8% | $246.3M-3.2% | $254.5M+22.4% | $208.0M |
| Free Cash Flow | $2.4B | $2.1B-24.7% | $2.7B+114.3% | $1.3B+11.0% | $1.1B-66.2% | $3.4B-11.1% | $3.8B-42.0% | $6.6B+21.2% | $5.4B+47.1% | $3.7B-7.2% | $4.0B+21.2% | $3.3B+23.4% | $2.7B+26.5% | $2.1B+29.1% | $1.6B+7.0% | $1.5B |
| Investing Cash Flow | -$1.5B | -$1.4B-71.6% | -$799.2M+80.5% | -$4.1B-360.1% | $1.6B+379.7% | -$563.7M+7.4% | -$608.6M-229.4% | $470.5M+123.0% | -$2.0B+30.9% | -$3.0B-19.2% | -$2.5B+45.4% | -$4.6B-195.1% | -$1.5B+3.8% | -$1.6B-68.9% | -$950.3M+42.4% | -$1.7B |
| Financing Cash Flow | -$322.7M | -$301.9M+55.8% | -$683.5M-557.8% | $149.3M+108.5% | -$1.7B+16.2% | -$2.1B+60.4% | -$5.3B+10.0% | -$5.9B-31.0% | -$4.5B-87.9% | -$2.4B-126.1% | -$1.1B-234.4% | $783.1M+203.6% | -$755.9M-5.5% | -$716.5M+18.3% | -$877.5M-174.3% | -$319.9M |
| Share Buybacks | N/A | N/A | $0 | $0-100.0% | $750.0M-58.3% | $1.8B-73.1% | $6.7B+13.8% | $5.9B+34.8% | $4.4B+218.8% | $1.4B+36.5% | $1.0B-80.0% | $5.0B+463.8% | $886.8M+121.5% | $400.3M-59.3% | $984.7M+97.7% | $498.0M |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BIIB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.7%-0.4pp | 76.1%+1.9pp | 74.2%-3.4pp | 77.6%-3.2pp | 80.8%-5.8pp | 86.6%+0.2pp | 86.4%-0.1pp | 86.5%-0.2pp | 86.7%-0.4pp | 87.1%-1.4pp | 88.5%+0.6pp | 87.9%+0.3pp | 87.6%-2.5pp | 90.1%-0.6pp | 90.8% |
| Operating Margin | N/A | N/A | N/A | N/A | 25.9%-8.0pp | 33.8%-15.1pp | 49.0%+5.2pp | 43.8%+0.2pp | 43.5%-1.5pp | 45.0%-0.4pp | 45.4%+4.5pp | 40.9%+4.6pp | 36.3%+2.7pp | 33.6%-0.5pp | 34.2% |
| Net Margin | 13.1%-3.8pp | 16.9%+5.1pp | 11.8%-18.1pp | 29.9%+15.8pp | 14.2%-15.6pp | 29.8%-11.2pp | 41.0%+8.0pp | 32.9%+12.2pp | 20.7%-11.7pp | 32.3%-0.6pp | 33.0%+2.7pp | 30.3%+3.4pp | 26.9%+1.8pp | 25.0%+0.6pp | 24.4% |
| Return on Equity | 7.1%-2.7pp | 9.8%+1.9pp | 7.8%-14.9pp | 22.7%+8.5pp | 14.3%-23.1pp | 37.4%-6.7pp | 44.1%+10.2pp | 34.0%+13.8pp | 20.1%-10.4pp | 30.5%-7.3pp | 37.8%+10.7pp | 27.2%+5.6pp | 21.6%+1.8pp | 19.8%+0.6pp | 19.2% |
| Return on Assets | 4.4%-1.4pp | 5.8%+1.5pp | 4.3%-8.1pp | 12.4%+5.9pp | 6.5%-9.7pp | 16.3%-5.4pp | 21.6%+4.1pp | 17.5%+6.8pp | 10.7%-5.5pp | 16.2%-2.0pp | 18.2%-2.3pp | 20.5%+4.8pp | 15.7%+2.1pp | 13.6%0.0pp | 13.6% |
| Current Ratio | 2.68+1.3x | 1.35-0.6x | 2.00-1.0x | 2.99+1.2x | 1.830.0x | 1.84+0.1x | 1.72-0.6x | 2.320.0x | 2.34-0.2x | 2.550.0x | 2.60+0.6x | 2.04+0.2x | 1.81-0.1x | 1.96-1.3x | 3.26 |
| Debt-to-Equity | 0.34+0.1x | 0.27-0.2x | 0.460.0x | 0.47-0.1x | 0.58-0.1x | 0.69+0.4x | 0.33-0.1x | 0.46-0.4x | 0.88+0.9x | 0.000.0x | 0.00-0.3x | 0.32+0.3x | 0.070.0x | 0.10-0.1x | 0.16 |
| FCF Margin | 20.7%-7.4pp | 28.1%+15.2pp | 12.9%+1.7pp | 11.3%-19.5pp | 30.8%+2.5pp | 28.3%-17.4pp | 45.6%+5.4pp | 40.3%+10.3pp | 30.0%-4.7pp | 34.7%+4.2pp | 30.4%+3.1pp | 27.4%-2.9pp | 30.3%+0.8pp | 29.5%-0.6pp | 30.1% |
Similar Companies
Where Biogen Inc Ranks
Frequently Asked Questions
What is Biogen Inc's annual revenue?
Biogen Inc (BIIB) reported $9.9B in total revenue for fiscal year 2025. This represents a 2.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biogen Inc's revenue growing?
Biogen Inc (BIIB) revenue grew by 2.2% year-over-year, from $9.7B to $9.9B in fiscal year 2025.
Is Biogen Inc profitable?
Yes, Biogen Inc (BIIB) reported a net income of $1.3B in fiscal year 2025, with a net profit margin of 13.1%.
How much debt does Biogen Inc have?
As of fiscal year 2025, Biogen Inc (BIIB) had $3.0B in cash and equivalents against $6.3B in long-term debt.
What is Biogen Inc's gross margin?
Biogen Inc (BIIB) had a gross margin of 75.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Biogen Inc's net profit margin?
Biogen Inc (BIIB) had a net profit margin of 13.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biogen Inc's return on equity (ROE)?
Biogen Inc (BIIB) has a return on equity of 7.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biogen Inc's free cash flow?
Biogen Inc (BIIB) generated $2.1B in free cash flow during fiscal year 2025. This represents a -24.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biogen Inc's operating cash flow?
Biogen Inc (BIIB) generated $2.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Biogen Inc's total assets?
Biogen Inc (BIIB) had $29.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biogen Inc's capital expenditures?
Biogen Inc (BIIB) invested $153.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biogen Inc spend on research and development?
Biogen Inc (BIIB) invested $1.8B in research and development during fiscal year 2025.
What is Biogen Inc's current ratio?
Biogen Inc (BIIB) had a current ratio of 2.68 as of fiscal year 2025, which is generally considered healthy.
What is Biogen Inc's debt-to-equity ratio?
Biogen Inc (BIIB) had a debt-to-equity ratio of 0.34 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biogen Inc's return on assets (ROA)?
Biogen Inc (BIIB) had a return on assets of 4.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biogen Inc's Piotroski F-Score?
Biogen Inc (BIIB) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biogen Inc's earnings high quality?
Biogen Inc (BIIB) has an earnings quality ratio of 1.71x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Biogen Inc?
Biogen Inc (BIIB) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.